Table 2.

Baseline levels of biomarkers in the whole cohort (n = 238) with separate values for patients with progression (n = 74) and no progression (n = 51) at 10 years.

Baseline, median (IQR)Progression, median (IQR)No Progression, median (IQR)
OPG, pmol/l3.0 (2.2–4.0)2.9 (2.2–3.8)2.9 (2.3–4.2)
RANKL, pmol/l0.03 (0.01–0.11)0.03 (0.00–0.10)0.03 (0.00–0.10)
RANKL/OPG0.01 (0.001–0.04)0.01 (0.00–0.04)0.01 (0.00–0.04)
YKL-40, ng/ml62 (42–94)66* (39–109)50 (33–75)
COMP, units10.0 (8.3–11.8)9.8 (7.8–12.0)10.5 (8.2–12.2)
CTX-I, ng/ml0.38 (0.25–0.62)0.41** (0.31–0.75)0.32 (0.21–0.49)
C2C, ng/ml59 (51–68)59 (53–70)59 (50–69)
CRP, mg/l5 (2–14)6** (3–16)3 (1–8)
ESR, mm/h21 (10–36)26** (16–45)13 (7–26)
  • Change in van der Heijde-modified Sharp score for hands > 1 unit/year.

  • * p < 0.05 Mann-Whitney test;

  • ** p < 0.01 Mann-Whitney test. OPG: osteoprotegerin, RANKL: receptor activator of nuclear factor-κB, YKL-40: human cartilage glycoprotein-39, COMP: cartilage digomeric matrix protein, CTX-I: collagen cross-linked C-telopeptide, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate.